Last reviewed · How we verify
fast itraconazole tablet
Itraconazole is a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
Itraconazole is a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Fungal infections (aspergillosis, candidiasis, cryptococcosis, and other systemic mycoses).
At a glance
| Generic name | fast itraconazole tablet |
|---|---|
| Also known as | fast dissolving itraconazole tablet |
| Sponsor | University of Maryland, Baltimore |
| Drug class | Triazole antifungal |
| Target | Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
By blocking the conversion of lanosterol to ergosterol, itraconazole compromises the integrity and permeability of the fungal cell membrane, leading to cell death. This fast-dissolving tablet formulation is designed to improve bioavailability and onset of action compared to standard itraconazole formulations. The drug is effective against a broad spectrum of fungal pathogens including Aspergillus, Candida, and Cryptococcus species.
Approved indications
- Fungal infections (aspergillosis, candidiasis, cryptococcosis, and other systemic mycoses)
Common side effects
- Nausea
- Headache
- Diarrhea
- Abdominal pain
- Hypokalemia
- Hepatotoxicity
Key clinical trials
- Drug Interaction and Food Effect Study of CS0159 (PHASE1)
- A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008) (PHASE1)
- A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants (PHASE1)
- This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood (PHASE1)
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the Blood (PHASE1)
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (PHASE1)
- Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers (PHASE1)
- A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fast itraconazole tablet CI brief — competitive landscape report
- fast itraconazole tablet updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI